SHF Communication Technologies AG hebt Umsatz- und Ergebnisprognose für das Geschäftsjahr 2018 an
SHF Communication Technologies AG beschließt Delisting ihrer Aktien
Mitteilung über Eigengeschäfte von Führungskräften gem. Art. 19 MAR
China kommt zu RENÉ LEZARD
Umsatzwachstum im ersten Halbjahr von 31,8% - Halbjahresumsatz beträgt 149 Mio. Euro
KFM-Mittelstandsanleihen-Barometer - Die "6,00%-FCR Immobilien-Anleihe"
MELDUNG VOM 02.08.2017 10:10
Meldung drucken Artikel weiterleiten
Business news for the stock market
Pressefach Pressefach

Biofrontera AG: Ameluz® launch for Actinic Keratosis in Israel

Perrigo Israel will market Ameluz® and BF-RhodoLED® starting immediately

Leverkusen (pta012/02.08.2017/10:10) - Biofrontera AG (ISIN: DE0006046113), the specialist for the treatment of sun-induced skin cancer, today announced the market launch of Ameluz® and BF-RhodoLED® in Israel by Biofrontera's partner Perrigo.

Prof. Dr. Hermann Lübbert, CEO of Biofrontera, commented, "We are pleased to be working with Perrigo and believe they will be effective in launching the treatment in Israel, allowing more patients to benefit from our technology. We look forward to expanding our global footprint and this commercial launch in Israel represents another major milestone for our company, as our treatment is now available in 14 countries."

Ameluz®, a topical prescription drug, is used in combination with the medical device BF-RhodoLED® for photodynamic therapy treatment (PDT). The combination treatment is labeled for lesion- and field-directed treatment of actinic keratosis (AK) in the US, and additionally for the treatment of field cancerization and superficial and nodular basal cell carcinoma in the EU.

Perrigo is a global pharmaceutical company that is active for both medicinal products and devices, and garners a leading position in the field of dermatology in Israel. Biofrontera entered into a licensing agreement with Perrigo Israel in January 2014 for the marketing of Ameluz® and BF-RhodoLED® in Israel. In November 2014, Perrigo Israel filed the marketing approval dossier with the Ministry of Health in Israel (IMOH) and Ameluz® received approval in May 2016. Subsequently, BF-RhodoLED® lamp was registered in Israel in May 2017.

In Israel, Ameluz® and BF-RhodoLED® currently are approved for the treatment of AK. Discussions on label expansions on field cancerization and basal cell carcinoma are in progress with the Ministry of Health.

Enquiries, please contact:

Biofrontera AG
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0

IR Germany: Brainwell Asset Solutions
Jürgen Benker
+49 (0) 152 08931514

IR UK: Seton Services
Toni Vallen
+44(0) 20 7729 0805

IR and PR US: The Ruth Group
IR: Tram Bui
+1 646-536-7035
PR: Kirsten Thomas
+1 508-280-6592

About Biofrontera:
Biofrontera AG is a biopharmaceutical company specializing in the development, sale and distribution of dermatological drugs and medical cosmetics. The Leverkusen, Germany-based company, which has approximately 100 employees worldwide, develops and distributes innovative products for the care, protection and treatment of the skin. Biofrontera's combination lead product is topical prescription drug Ameluz® and medical device BF-RhodoLED® for the photodynamic therapy (PDT) treatment of superficial skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the U.S. since 2016. The Company also markets the Belixos® dermocosmetics series in the EU, which offers specialized care for damaged or diseased skin.

Biofrontera is the first German, founder-led pharmaceutical company to obtain both EU and U.S. approval for a medical drug it has developed itself. The Biofrontera Group was established in 1997 by current CEO, Prof. Dr. Hermann Lübbert, and is listed on the Frankfurt Stock Exchange (Prime Standard).

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.


Aussender: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Ansprechpartner: Investor & public relations
Tel.: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (share)
Börsen: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
Biofrontera AG